Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

Editor-in-Chief: Llerena, Adrián

Editorial Board Member: Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Hirata, Rosario / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Maitland-van der Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Nair, Sujit / Nofziger, Charity / Peiro, Ana / Sadee, Wolfgang / Salazar, Luis A. / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Shin, Jae-Gook / Visvikis-Siest, Sophie / Zanger, Ulrich M.

4 Issues per year


CiteScore 2016: 1.40

SCImago Journal Rank (SJR) 2016: 0.413
Source Normalized Impact per Paper (SNIP) 2016: 0.537

Online
ISSN
2363-8915
See all formats and pricing
More options …
Volume 26, Issue 4 (Dec 2011)

Issues

Relevance of pharmacogenomics for developing countries in Europe

Konstantinos Mitropoulos / Lindsey Johnson / Athanassios Vozikis / George P. Patrinos
Published Online: 2011-10-22 | DOI: https://doi.org/10.1515/DMDI.2011.028

Abstract

Pharmacogenomics holds promise of personalized treatment for patients suffering from many common diseases, particularly those with multiple treatment modalities. Owing to recent advances in the deciphering of the human genome sequence, high throughput genotyping technology has led to the reduction of the overall costs of genetic testing and allowed the inclusion of genotype-related dosing recommendations into drug package inserts, hence enabling the integration of pharmacogenomics into clinical practice. Although pharmacogenomics gradually assumes an important part in routine clinical practice in developed countries, many countries, particularly from the developing world, still do not have access either to the knowledge or the resources to individualize drug therapy. The PharmacoGenetics for Every Nation Initiative (PGENI) aims to fill this gap, by making pharmacogenomics globally applicable, not only by defining population-specific pharmacogenomic marker frequency profiles but also by formulating country-specific recommendations for drug efficacy and safety. This article aims to highlight the PGENI activities in Europe in an effort to make pharmacogenomics readily applicable in the European healthcare systems, particularly those in developing countries.

Keywords: allele frequencies; developing countries; marker; pharmacogenomics; single nucleotide polymorphisms

About the article

Corresponding author: George P. Patrinos, Department of Pharmacy, School of Health Sciences, University of Patras, University Campus, Rion, GR-26504, Patras, Greece Phone/Fax: +30-2610-969-834


Received: 2011-08-25

Accepted: 2011-09-16

Published Online: 2011-10-22

Published in Print: 2011-12-01


Citation Information: Drug Metabolism and Drug Interactions, ISSN (Online) 2191-0162, ISSN (Print) 0792-5077, DOI: https://doi.org/10.1515/DMDI.2011.028.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Konstantinos Mitropoulos, Hayat Al Jaibeji, Diego A. Forero, Paul Laissue, Ambroise Wonkam, Catalina Lopez-Correa, Zahurin Mohamed, Wasun Chantratita, Ming Ta Michael Lee, Adrian Llerena, Angela Brand, Bassam R. Ali, and George P. Patrinos
Human Genomics, 2015, Volume 9, Number 1
[2]
Sharon Marsh, Cristi R King, Derek J Van Booven, Jane Y Revollo, Robert H Gilman, and Howard L McLeod
Pharmacogenomics, 2015, Volume 16, Number 5, Page 441
[3]
Tibor van Rooij, Mary Roederer, Todd Wareham, Iris van Rooij, Howard L McLeod, and Sharon Marsh
Personalized Medicine, 2015, Volume 12, Number 2, Page 117
[4]
Thomas AC Reydon, Kostas Kampourakis, and George P Patrinos
Personalized Medicine, 2012, Volume 9, Number 6, Page 633
[5]
George P. Patrinos, Timothy D. Smith, Heather Howard, Fahd Al-Mulla, Lotfi Chouchane, Andreas Hadjisavvas, Sherifa A. Hamed, Xi-Tao Li, Makia Marafie, Rajkumar S. Ramesar, Feliciano J. Ramos, Thomy de Ravel, Mona O. El-Ruby, Tilak Ram Shrestha, María-Jesús Sobrido, Ghazi Tadmouri, Martina Witsch-Baumgartner, Bin Alwi Zilfalil, Arleen D. Auerbach, Kevin Carpenter, Garry R. Cutting, Vu Chi Dung, Wayne Grody, Julia Hasler, Lynn Jorde, Jim Kaput, Milan Macek, Yoichi Matsubara, Carmancita Padilla, Helen Robinson, Augusto Rojas-Martinez, Graham R. Taylor, Mauno Vihinen, Tom Weber, John Burn, Ming Qi, Richard G. H. Cotton, and David Rimoin
Human Mutation, 2012, Volume 33, Number 11, Page 1513
[6]
Lindsey Mette, Konstantinos Mitropoulos, Athanassios Vozikis, and George P Patrinos
Pharmacogenomics, 2012, Volume 13, Number 7, Page 803
[7]
Alessio Squassina, Giovanni Severino, Godfrey Grech, Anthony Fenech, Joseph Borg, and George P Patrinos
Pharmacogenomics, 2012, Volume 13, Number 5, Page 525
[8]
Konstantinos Mitropoulos, Federico Innocenti, Ron H van Schaik, Alexander Lezhava, Giannis Tzimas, Panagoula Kollia, Milan Macek, Paolo Fortina, and George P Patrinos
Pharmacogenomics, 2012, Volume 13, Number 4, Page 387

Comments (0)

Please log in or register to comment.
Log in